Syndax Pharmaceuticals (SNDX) Change in Receivables (2022 - 2026)

Syndax Pharmaceuticals' Change in Receivables history runs 5 years deep, the most recent figure standing at -$120000.0 for Q1 2026.

• On a quarterly basis, Change in Receivables fell 101.48% year-over-year to -$120000.0 in Q1 2026; TTM through Mar 2026 was -$1.8 million, a 118.7% decrease from a year earlier, with the FY2025 full-year figure at $6.4 million, down 15.34% from the prior year.
• Change in Receivables rose to -$120000.0 in Q1 2026 per SNDX's latest filing, from -$11.4 million in the prior quarter.
• Across five years, Change in Receivables topped out at $8.6 million in Q3 2022 and bottomed at -$11.4 million in Q4 2025.
• The 5-year median for Change in Receivables is $3.5 million (2024), against an average of $1.8 million.
• Biggest YoY gain for Change in Receivables was 6122.06% in 2024; the steepest drop was 9033.82% in 2024.
• Year by year, Change in Receivables stood at $4.5 million in 2022, then tumbled by 101.5% to -$68000.0 in 2023, then jumped by 6122.06% to $4.1 million in 2024, then plunged by 377.53% to -$11.4 million in 2025, then jumped by 98.94% to -$120000.0 in 2026.
• Per Business Quant, the three latest SNDX Change in Receivables figures stand at -$120000.0 (Q1 2026), -$11.4 million (Q4 2025), and $5.9 million (Q3 2025).